<DOC>
	<DOC>NCT00254293</DOC>
	<brief_summary>The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.</brief_summary>
	<brief_title>Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Meet ARA criteria for diagnosis of RA with active disease. RA diagnosis for at least 1 year. &gt; = 6 swollen joints. &gt; = 8 tender joints. Taking methotrexate (MTX) or MTX plus not more than 1 added oral DMARD for &gt; = 3 months and stable for 28 days prior to dosing. Serious acute or bacterial infection in last 3 months. Chronic or recurrent bacterial infections. History of TB within previous 3 years or old TB not adequately treated. Specific lab test abnormalities History of cancer within 5 years. Exposure to CTLA4Ig (Cytotoxic Tlymphocyte (Tcell)associated antigen 4Ig), belatacept, rituximab, efalizumab, alefacept, or other investigational drug or biologic. Treatment with hydroxychloroquine, azathioprine, leflunomide, immunoadsorption columns, mycophenolate mofetil, cyclosporine, DPenicillamine or calcineurin inhibitors. Exposure to live vaccines.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>